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Embryo viabilityThe possibility to genotype embryos prior to implantation would have advantages for increasing the speed of
selection of cattle. Reliable genotyping requires more DNA than can be obtained from biopsies of embryos, if
they are to remain viable. Multiple displacement ampliﬁcation (MDA) is a whole genome ampliﬁcation tech-
nique used to increase the amount of DNA from biopsies for analysis. Reduced genome coverage resulting in
Allele Drop Out (ADO) at heterozygous loci or missing genotypes are drawbacks of MDA.
The present article describes the correlation between the input DNA quantity or embryo biopsy size and MDA
success. Missing genotypes and ADO drastically increased when fewer than 30–40 cells or the genomic equiv-
alents were used. However, embryo viability was found to be reduced if biopsied with more than 10 cells.
Therefore, in vitro cell culture was investigated as a means to increase the number of cells available and
the genotyping reliability.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Obtaining the genome-wide genotype of bovine embryos used in
assisted reproduction techniques would beneﬁt the cattle industry
by increasing the rate of genetic gain in selection programmes.
Genotyping at the time of embryo collection from super-ovulated
donors, or at the time of blastocyst formation for embryos produced
in vitro would allow the calculation of genomic breeding values for
individual embryos and hence the selection of those with the highest
breeding values. This approach has two advantages for the breeding
industry: 1) a 9 month increase in the rate of genetic gain, and
2) only embryos with the desired genotypes would be implanted,
therefore ensuring the best use of recipients. To carry out the
genotyping, the embryos are usually biopsied at the blastocyst stage
and the biopsied embryos then stored frozen until the genotyping
and genomic breeding estimates are obtained.
The genotyping of a limited number of loci, e.g. for the sex determi-
nation is carried out directly on the embryo biopsy [1], however, ge-
nome wide genotyping requires more DNA than can be obtained from
the few cells recovered by the embryo biopsies. Therefore an ampliﬁca-
tion step is necessary, which can be performed by various whole ge-
nome ampliﬁcation (WGA) techniques. Amongst these techniques,
multiple displacement ampliﬁcation (MDA) has been shown to have
the best performance [2,3]. MDA uses random primers that cover theri).
rights reserved.genome to initiate DNA replication by the Phi29 polymerase. The
Phi29 displacement activity unwinds the double helix and makes the
DNA accessible to additional primers and polymerase, resulting in an
exponential isothermal ampliﬁcation of the template [4]. MDA efﬁcien-
cy is affected by DNA quality and quantity and stochastic effects which
results in the uneven and incomplete ampliﬁcation of the genome. The
extent of genome ampliﬁcation is not necessarily proportional to the
starting amount of DNA. The unbalanced ampliﬁcation of heterozygote
loci can lead to Allele DropOut (ADO).Moreover, ampliﬁcation artefacts
could cause the appearance of new alleles at non-polymorphic loci, a
phenomenon known as Allele Drop In (ADI). The failure to amplify a ge-
nomic region will result in the loss of information.
The reported ADO rates for genome ampliﬁcation of single cells vary
from 4% up to 50% or more [2,5–9]. The completeness ofWGA increases
with the amount of starting material, although the minimum quantity
of DNA that can be used in a MDA reaction has not been deﬁned.
Some authors claim reasonable quality (b10% errors) can be achieved
with as few as 10 cells [5,10,11], whereas others suggest at least 100
genome equivalents are necessary [12]. MDA kits (Replig, QIAGEN and
GenomiPhi V2, GE Healthcare) recommend the use of 1 to 10 ng of
DNA, which corresponds to about 200 to 2000 genome equivalents.
In the present work SSR markers and the Illumina 54K SNP panel
were used to deﬁne the correlation between the starting amount of
template DNA and the quality of WGA, using DNA dilutions and bovine
embryo biopsies. Cloned embryos derived from somatic cell nuclear
transfer, and hence with identical genotype, were cultured in vitro up
to the blastocyst stage then different sizes of biopsy taken. Cells from
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Fig. 2. The WGA product quality assessed with SSR markers is reported for cultured
embryo (100 and 1000) and embryo biopsies of various sizes (10 to 75), as box plots.
Red lines for the 10 and 20 cell series represent the average values.
25A. Lauri et al. / Genomics 101 (2013) 24–29the biopsies were either used directly for WGA, or cultured further
in vitro to obtain a greater number of cells for WGA. Results were
conﬁrmed in blind experiments with embryos of unknown genotype
obtained from in vitro fertilization.
2. Results
2.1. WGA quality assessment from DNA dilutions
The quality of the WGA was assessed in relation to the quantity of
input DNA, using serial dilutions of DNA corresponding to 600, 200,
100, 75, 50, 40, 30, 20, 15, 10 and 1 bovine genomic equivalent(s) (ge).
The ampliﬁcation products were genotyped using 12 SSR markers and
the genotypes obtained were compared with that of the un-ampliﬁed
control DNA. The quality of ampliﬁcation was directly proportional to
the amount of input DNA used as the WGA template (Fig. 1). Samples
starting from more than 200 ge had the highest quality, with no differ-
ences in genotype with respect to the control. The quality decreased
from 100 to 40 ge, although in all cases at least 94% accuracy of geno-
typeswere obtained. Below30 ge the quality of the ampliﬁcationwas re-
duced to values between 40% and 70%, with high variability among
repetitions.
2.2. WGA quality assessment from embryo biopsies
Embryo biopsies containing 75, 40, 30, 20 and 10 cells obtained from
cloned embryos, and therefore of identical genotypes, and biopsies cul-
tured to 100 and 1000 cells (8 replicates per sample type) were tested
as starting material for WGA. Samples starting from 30 or more cells
gave genotypes matching that of the control, whereas the ampliﬁcation
quality was lower for samples starting from 20 and 10 cells, which had
lower success and a more variable quality (91.25% and 82.50%, with a
standard deviation of 19.44% and 35.00%, respectively) (Fig. 2).
The SSR genotyping of WGA products obtained from DNA dilutions
and from embryo biopsies showed that 30 cells was the minimum
biopsy size necessary to obtain high quality ampliﬁcation (>94% of cor-
rect allele calls). A further increase in WGA quality may be expected
using a larger number of input cells, however, biopsies of more than
30 cells are likely to reduce embryo viability. Biopsies of 20–30 cells
were therefore cultured to increase cell numbers, prior to ampliﬁcation.
2.3. Whole Genome Genotyping of WGA products
WGA products obtained from the least invasive biopsy (10 cells,
16 replicates), the best viability/WGA quality ratio (30 cells, 16 repli-
cates) and the highest quality (cultured biopsies, 12 replicates) were
compared by Whole Genome Genotyping (WGG) using the Illumina0%
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Fig. 1. The WGA product quality, assessed with SSR markers, is reported for serial dilu-
tions of pure DNA, as box plots.Bovine 54K SNP panel. The Genome Coverage (GC), the Allele Drop
Out (ADO) and the Allele Drop In (ADI), were used to evaluate the ef-
ﬁciency and the quality of ampliﬁcation. More than 30% of the 10 cell
samples (5/16) showed better than 85% genotyping success with an
average of 72.45% across all the samples. Only 1 of the 30 cell samples
had below 85% success and half of the samples were above 95%. The
cultured biopsies had slightly higher GC with only 2 out of 12 samples
having a genotyping success rate below 85% and with an average of
96.04% (Figs. 3 and 4).
The ADO decreased from 12.60% to 1.41% between 10 to 30 cells
as the starting point. For the 10 cell series 5/16 of the samples showed
ADO below 10%, while for the 30 cell series all samples had and ADO
below 10% and 10/16 (62.50%) of the samples showed ADO below 1%.
For the cultured biopsies 10/12 of the samples had an ADO below 1%.
The ADI showed a comparable reduction from 10 to 30 cells and the
cultured biopsies showed the lowest ADI (Figs. 3 and 4).
GC, ADO and ADI were correlated in all sets of samples (Fig. 3). This
was particularly evident in the 10 cell samples, where the highest
GC values corresponded to the lowest ADO and ADI. Considering all
samples, the pair wise correlation between GC, ADO and ADI ﬁtted
with a linear curve (Fig. 5).
2.4. Blind genotyping
Ten cell biopsies of sixteen embryos with unknown genotype
were analysed with the 54K SNP Illumina panel and ADO, ADI and
GC were determined as described in Section 4.8. The average ADO
was 13.75%, with 12.50% of the samples having an ADO lower than
1% and 37.50% of the samples between 1% and 10%. The average ADI
was 3.34%, with 81.25% of the samples with a value below 1% and
6.25% between 1% and 10%. The average GC was 81.42%, with 75% of
the samples above 85% and 6.25% of the samples above 95% (Fig. 4).
As with the cloned embryos, the ADO and ADI were higher for sam-
ples with lower GC values (Fig. 3).
A Student t test was used to investigate if the differences between
the two data sets obtained for 10 cells (blind and cloned, reported in
Fig. 3) were statistically relevant. The results showed no signiﬁcant
difference between the two sample sets for ADO, ADI and GC.
2.5. Biopsied embryo viability
The viability of a biopsied embryo is related to the size of biopsy, and
is also affected by freezing, which is necessary to store embryos prior to
transfer to the recipient. In order to assess the viability of embryos with
different sizes of biopsy, embryoswere frozen immediately after biopsy
10 cells
A.10 18,59% 1,00% 1,14% 0,05% 6,27% 93,73%
B.10 21,49% 1,46% 1,06% 0,04% 7,07% 92,93%
C.10 28,53% 2,35% 8,28% 0,82% 14,23% 85,77%
D.10 32,92% 4,18% 5,94% 0,52% 13,87% 86,13%
E.10 33,96% 4,96% 6,23% 0,47% 14,38% 85,62%
F.10 42,96% 11,46% 16,86% 2,10% 24,53% 75,47%
G.10 43,97% 11,71% 14,76% 1,26% 23,35% 76,65%
H.10 42,35% 11,84% 15,82% 1,55% 23,62% 76,38%
I.10 47,36% 13,09% 24,33% 3,15% 31,10% 68,90%
J.10 43,56% 13,57% 16,18% 2,05% 24,23% 75,77%
K.10 44,75% 13,71% 21,22% 3,09% 28,14% 71,86%
L.10 70,60% 15,70% 70,74% 12,73% 70,70% 29,30%
M.10 43,39% 18,81% 16,30% 1,74% 24,27% 75,73%
N.10 69,60% 21,54% 69,75% 8,36% 69,70% 30,30%
O.10 53,84% 22,76% 42,65% 7,57% 45,94% 54,06%
P.10 40,47% 33,48% 10,66% 0,47% 19,42% 80,58%
AVERAGE 42,40% 12,60% 21,37% 2,87% 27,55% 72,45%
30 cells
A.30 9,54% 0,24% 0,95% 0,04% 3,48% 96,52%
B.30 8,79% 0,28% 0,89% 0,04% 3,22% 96,78%
C.30 9,71% 0,36% 0,73% 0,03% 3,37% 96,63%
D.30 11,56% 0,40% 0,76% 0,03% 3,94% 96,06%
E.30 13,75% 0,49% 1,09% 0,05% 4,81% 95,19%
F.30 12,68% 0,50% 0,92% 0,03% 4,38% 95,62%
G.30 12,69% 0,54% 0,80% 0,03% 4,29% 95,71%
H.30 12,92% 0,58% 0,93% 0,04% 4,46% 95,54%
I.30 15,62% 0,77% 1,02% 0,04% 5,31% 94,69%
J.30 20,73% 0,86% 5,57% 0,57% 10,02% 89,98%
K.30 22,31% 1,32% 10,43% 1,20% 13,92% 86,08%
L.30 19,33% 1,36% 1,75% 0,06% 6,92% 93,08%
M.30 22,32% 1,74% 1,89% 0,09% 7,90% 92,10%
N.30 22,80% 2,01% 1,21% 0,06% 7,56% 92,44%
O.30 26,94% 2,74% 1,97% 0,08% 9,31% 90,69%
P.30 41,16% 8,30% 20,45% 2,82% 26,54% 73,46%
AVERAGE 17,68% 1,41% 3,21% 0,33% 7,46% 92,54%
cultured biopsies
A.cult 5,00% 0,02% 1,46% 0,03% 2,50% 97,50%
B.cult 4,79% 0,04% 1,72% 0,05% 2,62% 97,38%
C.cult 3,83% 0,05% 0,96% 0,01% 1,80% 98,20%
D.cult 5,56% 0,09% 1,22% 0,02% 2,49% 97,51%
E.cult 4,60% 0,11% 1,01% 0,01% 2,07% 97,93%
F.cult 4,22% 0,16% 0,81% 0,01% 1,81% 98,19%
G.cult 5,50% 0,17% 1,70% 0,04% 2,82% 97,18%
H.cult 10,10% 0,32% 1,30% 0,03% 3,89% 96,11%
I.cult 8,97% 0,46% 1,68% 0,04% 3,82% 96,18%
J.cult 10,87% 0,77% 1,81% 0,05% 4,48% 95,52%
K.cult 12,15% 1,07% 2,05% 0,09% 5,02% 94,98%
L.cult 28,18% 2,54% 8,44% 0,43% 14,25% 85,75%
AVERAGE 8,65% 0,48% 2,01% 0,07% 3,96% 96,04%
blind
5266M01 34,78% 36,28% 9,30% 0,47% 16,70% 83,30%
5266M02 31,45% 8,44% 0,66% 0,04% 12,34% 87,66%
8946F02 37,80% 24,57% 3,35% 0,13% 13,47% 86,53%
8946F06 20,57% 2,05% 0,31% 0,04% 6,68% 93,32%
8946F08 34,62% 22,25% 3,24% 0,20% 13,14% 86,86%
8946M01 15,04% 0,82% 0,49% 0,03% 5,32% 94,68%
8946M03 36,36% 51,40% 27,81% 1,43% 30,56% 69,44%
8946M04 35,68% 17,05% 0,56% 0,04% 14,58% 85,42%
8946M05 59,67% 9,23% 58,63% 36,91% 58,62% 41,38%
8946M07 15,93% 1,47% 0,21% 0,03% 5,43% 94,57%
8946M10 14,25% 0,65% 0,17% 0,02% 4,55% 95,45%
8946M11 19,72% 2,53% 0,28% 0,02% 6,52% 93,48%
8958F01 34,09% 11,28% 0,81% 0,03% 10,97% 89,03%
8958F02 24,15% 10,84% 0,84% 0,04% 8,33% 91,67%
8958F04 78,21% 12,06% 78,43% 13,94% 78,64% 21,36%
8958M03 33,89% 9,00% 1,27% 0,04% 11,46% 88,54%
AVERAGE 32,89% 13,75% 11,65% 3,34% 18,58% 81,42%
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Fig. 3. The results from Whole Genome Genotyping with the Illumina Bovine 54K panel are reported. Data represent the Allele Drop Out (ADO), Allele Drop In (ADI) and the
Genome Coverage (GC). Percentage of negative calls (MISS) among the homozygote, heterozygote or all loci is also shown (HET, HOM and TOT, respectively). Charts report the
values ordered by growing ADO. In the three lower charts (30 cells, cultured and blind samples). Y axes values are reported on a logarithmic scale.
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Fig. 4. The ADO, ADI andGC shown in Fig. 3 are reported grouped in series (b1%, included between1% and 10%,>10%, for ADI andADO; b85%, included between85% and 95%,>95%, for GC).
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Fig. 5. The correlation between GC and ADO (Panel A) and GC and ADI (Panel B) are
shown by plotting all the values reported in Fig. 3 and drawing regression lines.
27A. Lauri et al. / Genomics 101 (2013) 24–29of 10 cells (28 replicates) or 30 cells (32 replicates), then thawed and
cultured in vitro for 48 h. The same procedure was used with
un-biopsied embryos, for comparison (52 replicates). Embryos follow-
ing the 10 cell biopsy showed a survival rate of 89% whereas viability
of embryos from a 30 cell biopsy was reduced to 62%. Control
un-biopsied embryos showed a survival rate of 90%.
3. Discussion
Genotyping an embryo from biopsied cells can facilitate the esti-
mation of the genomic breeding values for that embryo and hence ge-
netic selection could be achieved even before implantation ensuring
the selection of the best embryos for breeding. For cattle this would
signiﬁcantly increase the rate of breeding improvement. However
there is a trade off between genotyping success, the number of cells
in the biopsy and embryo survival. Generally, the lower the number
of cells, or starting DNA, the lower the success of the WGA, but the
higher the survival rate of the embryos.
In the present work, the relationship between the amount of
starting material and WGA ampliﬁcation quality was investigated
using dilutions of puriﬁed DNA and different numbers of cells from
embryo biopsies. The results of genotyping with 12 SSR markers
were comparable using cells or the same genome equivalents of puri-
ﬁed DNA as starting material. The lower limit cut off before WGA
problems were observed was approximately 30–40 cells or ge. The
consistency of these results suggests that there is no inhibitory effect
from components in the embryo lysate and hence a DNA puriﬁcation
step before theWGA is not necessary. The results presented here sug-
gest that the pre-treatment of samples with proteinase K claimed to
destroy ampliﬁcation inhibitors before WGA and improve efﬁciency
[13] also seems to be unnecessary.
The effect of splitting biopsies into smaller samples to be ampliﬁed
independently then analysed as a MDA DNA pool was not investigated.
Nevertheless, results reported here (Fig. 2) and in a previous
28 A. Lauri et al. / Genomics 101 (2013) 24–29publication [5] would suggest a roughly linear relationship between
biopsy size and average ampliﬁcation quality, for samples with less
than 30 cells. If so, the expected output of such of an approach would
not be an improvement over the ampliﬁcation of the whole sample.
The lower limit for DNA ampliﬁcation is most likely because of
stochastic effects which result in incomplete coverage of the genome
and the uneven ampliﬁcation of different regions which will result in
missing genotypes. The unequal ampliﬁcation of the DNA as one of
the causes of ADO and negative calls was conﬁrmed by the direct cor-
relation between GC and ADO reported in this study. The appearance
of new alleles (ADI) also seems to be higher at lower GC values
and this presumably reﬂects an overall higher copying error rate,
although the reason has not yet been completely understood [14].
To reduce the loss of vitality of the embryo after the biopsy, the
biopsies should be restricted to as few cells as possible. The data
presented here show that embryos with biopsies of 10 cells have a
survival rate comparable to that of un-biopsied embryos and 27%
higher viability than the embryos from which 30 cell biopsies are
taken, while the former have an 11% higher chance of missing an
allele in homozygote loci due to poorWGA. Pregnancy rates following
the transfer of frozen thawed biopsied embryos suggest that there is
only minor loss of viability following a biopsy of 10 cells, as compared
with intact embryos [5]. To overcome the conﬂict between embryo
viability and genotyping success the number of cells can be increased
by in vitro cell culture. Using 20–30 cell biopsies cultured to about
1000 cells increases the reliability of WGA. However the additional
time and costs required for the culture step makes this not a viable
approach for commercial use.
When using unknown samples, ADO rate can be estimated from the
GC represented by the call rate. If the genotypes of the two parents are
known, theADO, and consequently the genotyping reliability, can be es-
timated more accurately on the basis of the loci that are expected to be
heterozygous. In current genomic selection programmes, high density
SNP information is often recovered from low density genotyping using
data from parents and relatives and statistical approaches to impute
missing genotypes [15]. A similar approach can be used to verify and
recover data for embryos genotyped using WGA.
4. Materials and methods
4.1. Production of cloned bovine embryos
Cloned embryos were produced as described by Galli et al. [16].
Brieﬂy, bovine ovaries were collected from slaughtered cows, follicles
over 3 mm in diameter were dissected, oocytes recovered and trans-
ferred to maturation medium (TCM-199 supplemented with 10% (v/v)
foetal calf serum, gonadotropins (0.05 IU/ml FSH and 0.05 IU/ml LH)
and growth factors (50 ng/ml long-EGF and 10 ng/ml bFGF) [17,18].
Oocytes were cultured at 38.5 °C and 5% CO2 in humidiﬁed air for
16 h–20 h after which the cumulus cells were removed and the oocytes
were enucleated by the aspiration of polar body and associated meta-
phase II plate in minimal volume of ooplasm. The somatic cells were
obtained by trypsinisation of a ﬁbroblast cell line derived from a skin
biopsy of a Holsetin Fresian bull. A single somatic cell was fused to
each enucleated oocyte and chemically activated to induce cell division.
Developing embryos were cultured in a modiﬁed Synthetic Oviduct
Fluid medium for 7–8 days after activation until they reached the
blastocyst stage.
4.2. Embryo biopsy and culture of biopsied cells
Blastocyst stage embryos were biopsied using a microblade
(Bioniche, Pulman Washington, USA) mounted on a Leitz (Germany)
micromanipulator. The biopsied cells were either frozen prior to DNA
extraction, genotyping, or cultured in vivo by transferring them
into micro-drops of 40 μl culture medium consisting of DMEM-F12supplemented with BSA (10 mg/ml) and N2 (Invitrogen) under oil.
The biopsies were cultured for 4–5 days in order to obtain
100–2000 cells which were then frozen.
4.3. Embryo freezing
Following biopsy embryos were frozen in hepes-SOF containing
6 mg/ml of BSA and 1.5 M ethylene glycol, using an embryo freezer
methanol bath and following a standard freezing curve (ﬁrst holding
at−6 °C, then cooling to−32 °C at 0.5 °C per minute, before plunging
in liquid nitrogen). Embryo survival following biopsy and freezing was
assayed by thawing a sample of embryos inwater at 25 °C and culturing
them for 48 h in SOF medium. Viability was measured as the rate of
embryo survival (expanded or hatched blastocyst stage embryos/total
embryos thawed) at 48 h.
4.4. In vitro ﬁbroblast culture and DNA extraction
Primary ﬁbroblasts were obtained from a skin biopsy which was cut
into small pieces and the tissue fragments plated onto on gelatinised cul-
ture dishes in TCM199/DMEM (1:1) medium supplemented with 10%
foetal calf serum. The same ﬁbroblast cell line was used to generate all
the cloned bovine embryos by somatic cell nuclear transfer, and for
trail WGA DNA analyses. Genomic DNA was extracted using the Gentra
Puregene kit (QIAGEN) following the manufacturer's instructions.
DNA was quantiﬁed using a Nanodrop (Thermo Scientiﬁc). For dilution
studies 1 genome equivalent was considered to be equivalent to 5 pg
of DNA.
4.5. WGA ampliﬁcation from embryo biopsies
Frozen embryo biopsies were thawed for 15′ at room temperature,
then re-frozen at−20 °C for 30′. This slow freezing/thawing (repeated
3 times) facilitated the release of DNA. The WGA was carried out using
theRepli-gMini Kit (QIAGEN) following themanufacturer's instructions
for 16 h at 30 °C. Following the reaction 5 μl were analysed on an EtBr
stained agarose gel to verify the presence of an ampliﬁcation product.
4.6. Blind samples
Sixteen embryos with unknown genotype, resulting from in vitro
fertilization of egg cells from 3 donors with sperm cells from one
bull, were sampled with 10 cell biopsies and analysed by WGG. The
genotypes of the 4 parents were also assessed from genomic DNA
extracted from blood samples or semen (see Section 4.4).
4.7. SSR markers
The survey of SSR markers was carried out by amplifying the 12
loci with the primers reported in Table 1, using about 50 ng of the
WGA product per reaction. The PCR ampliﬁcation conditions were:
an initial denaturation (10′ at 94 °C) was followed by 31 cycles (45″
at 94 °C; 45″ at 59 °C; 60″ at 72 °C) and a ﬁnal extension (30′ at
72 °C). The PCR products were analysed using an ABI PRISM 3100
Genetic Analyze and the genotypes assigned using ABI-PRISM
Genescan and ABI-PRISM Genotyper software.
WGA products and 1 un-ampliﬁed control were genotyped for the
12 SSRmarkers. The control proﬁle included 8 heterozygote loci and 4
homozygote loci, for a total of 20 alleles. The quality of the ampliﬁca-
tion was assessed as the average percentage, out of eight repetitions
per dilution, of alleles that matched the control.
4.8. WGA quality parameters
WGA products from the cloned embryos were genotyped for the
Illumina bovine 54K SNP panel. Genomic DNA extracted from the
Table 1
SSR markers and primers used in this study. The ampliﬁcation range and the ampliﬁcation failure rate per allele are reported per each SSR marker.
Marker — primer name Sequence Fluorochrome Colour Range Amp failure per allele
TGLA227 F CGA ATT CCA AAT CTG TTA ATT TGC T VIC Green 75–105 bp 10.4%
TGLA227 R ACA GAC AGA AAC TCA ATG AAA GCA – –
TGLA126 F CTA ATT TAG AAT GAG AGA GGC TTC T VIC Green 109–125 bp 4.2%
TGLA126 R TTG GTC TCT ATT CTC TGA ATA TTC C – –
ETH3 F GAA CCT GCC TCT CCT GCA TTG G FAM Blue 101–131 bp 16.7%
ETH3 R ACT CTG CCT GTG GCC AAG TAG G – –
BM2113 F GCT GCC TTC TAC CAA ATA CCC NED Yellow 121–143 bp 17.4%
BM2113 R CTT CCT GAG AGA AGC AAC ACC – –
ETH225 F GAT CAC CTT GCC ACT ATT TCC T FAM Blue 136–162 bp 21.9%
ETH225 R ACA TGA CAG CCA GCT GCT ACT – –
TGLA122 F CCC TCC TCC AGG TAA ATC AGC VIC Green 135–187 bp 22.2%
TGLA122 R AAT CAC ATG GCA AAT AAG TAC ATA C – –
TGLA53 F GCT TTC AGA AAT AGT TTG CAT TCA NED Yellow 152–188 bp 17.4%
TGLA53 R ATC TTC ACA TGA TAT TAC AGC AGA – –
BM1824 F GAG CAA GGT GTT TTT CCA ATC FAM Blue 174–194 bp 19.4%
BM1824 R CAT TCT CCA ACT GCT TCC TTG – –
INRA23 F GAG TAG AGC TAC AAG ATA AAC TTC VIC Green 196–222 bp 19.4%
INRA23 R TAA CTA CAG GGT GTT AGA TGA ACT C – –
ETH10 F GTT CAG GAC TGG CCC TGC TAA CA NED Yellow 209–227 bp 12.2%
ETH10 R CCT CCA GCC CAC TTT CTC TTC TC – –
SPS115 F AAA GTG ACA CAA CAG CTT CTC CAG NED Yellow 246–264 bp 6.3%
SPS115 R AAC GAG TGT CCT AGT TTG GCT GTG – –
BM1818 F AGC TGG GAA TAT AAC CAA AGG FAM Blue 250–280 bp 1.4%
BM1818 R AGT GCT TTC AAG GTC CAT GC – –
29A. Lauri et al. / Genomics 101 (2013) 24–29donor ﬁbroblasts was used as benchmark for the WGA product qual-
ity assessment.
Genome coverage (GC) was calculated from the call rate, i.e. the
number of SNP with a positive call on the total number of SNP. The
ADO rate was calculated with respect to the heterozygote loci
(16055), the ADI rate was calculated with respect to the homozygote
loci (38554).
For blind samples, only SNP located on the autosomes and that
were correctly genotyped in both parents were considered. ADI was
calculated based on the expected homozygote loci, i.e. those that
resulted from loci homozygous for the same allele in the two parents.
Similarly, ADO was calculated based on expected heterozygote loci,
i.e. those that resulted from parental loci homozygous for different
alleles. The GC was deﬁned as the total number of positive calls on
the whole set of loci.
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